Kalvista Pharmaceuticals, Inc. · NASDAQ:KALV
Kalvista Pharmaceuticals — Q2 2025 Earnings Presentation
19 slides from Kalvista Pharmaceuticals's earnings presentation, Sep 11, 2025
Slide 1: Corporate Overview
Corporate Overview September 2025
Slide 2: Forward-looking statements
Forward-looking statements This presentation and the accompanying oral commentary contain forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to our management. For this purpose, any statements that are not statements of histor
Slide 3: EKTERLY approved by U.S. FDA July 2025
EKTERLY® approved by U.S. FDA July 2025 EKTERLY (sebetralstat) is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older. Please see Prescribing Information at KalVista.com. 3
Slide 4: Hereditary angioedema: a rare disease defined by unpredictable swelling attacks
Hereditary angioedema: a rare disease defined by unpredictable swelling attacks Approximately Prevalence: 1 in 35,000 - 1 in 50,000 people worldwide1,2 • Life-threatening if the upper Lifelong attacks of airway is involved3 debilitating swelling in • Attack severity may increase the face, extremitie
Slide 5: EKTERLY Unmet Need & Clinical Data
EKTERLY Unmet Need & Clinical Data
Slide 6: Ideal Management of HAE
Ideal Management of HAE Treatment goals: achieve total disease control and normalize patients' lives1,2 All Patients Long-term prophylaxis in Effective On-Demand Treatment appropriate patients: Should ideally offer: • High disease activity • Rapid symptom relief • Poor patient quality of life • Easy
Slide 7: Treatment guidelines reinforce four key recommendations
Treatment guidelines reinforce Injectable on-demand therapies come four key recommendations for with their own set of challenges: the treatment of HAE attacks 1-3 1/3 to 1/2 of attacks go untreated, including among patients on long- 1 Treat attacks as early as possible after term prophylaxis6 recogn
Slide 8: Management of HAE prior to EKTERLY
Management of HAE prior to EKTERLY Inadequate control with parenteral on-demand treatment and disproportionate use of LTP Long-term prophylaxis Injectable or intravenous on-demand in majority of patients On-demand treatment is underutilized • Complex logistics and painful • High treatment burden • D
Slide 9: Management of HAE with EKTERLY
Management of HAE with EKTERLY Poised to Become the Foundational HAE Treatment EKTERLY On-Demand Treatment Long-term prophylaxis in appropriate patients1,2 First and only oral on-demand HAE treatment 1. Busse PJ, et al. J Allergy Clin Immunol Pract. 2021;9(1):132-150.e3. 2. Maurer M, et al. Allergy.
Slide 10: Data releases in 2025 include
Attacks treated as 48 of June 30, 20255 Open-label extension trial1 laryngeal attacks treated Data releases in 2025 include No reports of 2,323 ~2,300 difficulty swallowing Median time to treatment: 10 min4 attacks treated with X Median time to end of attack progression: 19.8 min3 600mg EKTERLY 463
Slide 11: EKTERLY Commercial Strategy & Launch
EKTERLY Commercial ® Strategy & Launch
Slide 12: EKTERLY: The first and only oral on-demand HAE treatment
EKTERLY: The first and only oral on-demand HAE treatment Poised to be the foundational HAE treatment that enables early treatment of all attacks to improve outcomes Early Can be taken immediately Treatment upon attack recognition Injectable-like Proven to halt attack progression quickly and safely w
Slide 13: EKTERLY launch metrics highly encouraging
EKTERLY launch metrics highly encouraging 8-week period ended August 29 Strong early Broad physician Early favorable 4,000+ individuals demand with 460 adoption across 253 reimbursement by enrolled in patient patient start forms unique prescribers both commercial database received in first eight wit
Slide 14: Pathway to becoming standard of care for HAE
Pathway to becoming standard of care for HAE GROW MARKET SHARE GROW ATTACK TREATMENT RATE Expand utilization Earlier attack treatment Accelerate TODAY adoption Treatment of all attacks EKTERLY Broaden to 2,000 HCPs Opportunity: Drive early All on-demand users US on-demand Leverage formulary demand c
Slide 15: EKTERLY poised for rapid global expansion
EKTERLY poised for rapid global expansion Rest of world launches UK launch Japan launch* Germany launch* US launch underway 2H 2025 2026 *Anticipated, subject to regulatory approval 15
Slide 16: Well-positioned for global success
Well-positioned for global success Favorable market dynamics Strong clinical data Deep HAE experience High unmet need Clinical safety profile no different Commercial team with significant Stable demand from placebo experience in HAE and rare Robust efficacy demonstrated in all disease Low competitiv
Slide 17: Factor XIIa
Factor XIIa
Slide 18: Factor XIIa program continues to advance
Factor XIIa program continues to advance Strong biology FXIIa sits at the top of multiple pathways • Likely plays a role in multiple disease states involving edema, thrombosis and inflammation Compelling assets Portfolio of FXIIa inhibitor compounds with potential for clinical development • High pot
Slide 19: Nasdaq: KALV
Nasdaq: KALV
KalVista Pharmaceuticals — Q2 2025 Earnings Presentation on 6ix